Press release

Dr. Roderick Scott joins Sequence Bio as Chief Science Officer

February 22, 2022

dr. roderick scott joins sequence bio as chief science officer 

Newfoundland and Labrador-based biotechnology company Sequence Bio is pleased to welcome Dr. Roderick Scott to its executive team as Chief Science Officer. 

Dr. Scott is a top industry scientist with over 20 years experience across all stages of drug discovery and therapeutic development from identifying and validating suitable drug targets to leading compounds through preclinical development and into clinical trials.

He received his PhD (Neuroscience) from Columbia University and completed his post-doctoral studies at Rockefeller University. He then joined OSI Pharmaceuticals to work on the “Helicon” project, a collaboration between OSI Pharmaceuticals, Hoffmann-La Roche AG (Roche) and Cold Spring Harbor Laboratory that focused on long term memory. This project became Helicon Therapeutics, where Dr. Scott was the company’s first employee. Helicon Therapeutics then transitioned to Dart Neuroscience as it grew to over 250 people. During this time, Dr. Scott led the Neuroscience drug discovery program, working on eight different compounds approved for Investigational New Drug submissions with the United States Food and Drug Administration. His most recent role was at Leading Bioscience (now known as Palisades Bio), where he was Vice President of Research. 

“Sequence Bio is uniquely positioned to make a meaningful, global impact on the ways that we approach drug discovery and develop treatments for those in need,” says Dr. Scott. “This is an exciting opportunity to work with the people of Newfoundland and Labrador, and apply systems biology and cutting-edge technology to make a significant difference in the lives of people around the world.”

As Chief Science Officer, Dr. Scott will lead all aspects of Sequence Bio’s research, including the continued growth and operations of its drug discovery team. 

“​Rod is a world-class scientist who brings a wealth of unique experience and a passion for innovating drug discovery,” says Chris Gardner, chief executive officer of Sequence Bio. “We’re working on something really special that has the potential to help millions of people around the world, ​​and we continue to attract incredible local and global talent to our team to bring that goal to life. Dr. Scott recognizes the significance of that opportunity, and I’m proud he chose to put his skills and knowledge to work at a Sequence Bio.”

About Sequence Bio

Sequence Bio is a Newfoundland and Labrador-based biotechnology company. Headquartered in St. John's, we're a committed team of local and international experts united in our goal to benefit the lives of Newfoundlanders and Labradorians and others around the world for generations to come.

With research powered by the Newfoundland founder effect, Sequence Bio is taking a systems biology approach to discover the true signals of disease to accelerate the development of life-changing medicines. 

Learn more at SequenceBio.com and NLGenomeProject.ca

For additional information please contact

Adriann Kennedy
Manager, Integrated Communications
+1-800-296-3481 x745

Preface/disclaimer - Sequence Bio is planning to conduct research in Newfoundland and Labrador, and doing so in an ethical and transparent way is our first priority. Our efforts require approval by the Health Research Ethics Board (HREB). The words "believe","expect","anticipate", and similar expressions, among others, generally identify our intent and/or objective to undertake research in this province and may be subject to change after HREB Review.